mRNA-Based Designer APCs Elicit Robust CD8⁺ and CD4⁺ T Cell Responses
Yamano, T.; Hanayama, R.; Le, T. V.; Imai, S.; Fujitsuka, I.; Ueda, M.; Nakamae, S.; Mizukami, S.
Show abstract
mRNA-based therapeutics have demonstrated notable success in SARS-CoV-2 vaccines and are emerging in cancer immunotherapy. However, conventional mRNA cancer vaccines are limited by the low immunogenicity of tumor-associated and neoantigens. We addressed this limitation by formulating a modular, liposome-based mRNA cocktail comprising three distinct mRNAs encoding tumor antigen, the co-stimulatory molecule CD80, and membrane-tethered IL-2. Administration of this mRNA mixture transforms somatic cells into designer antigen-presenting cells (APCs) in vivo, which simultaneously express the antigen, a co-stimulatory molecule, and a cytokine. These designer APCs more effectively activated tumor antigen-specific CD8 T cells than mRNA encoding the antigen alone and elicited robust anti-tumor immune responses. In addition, substituting IL-2 in the mRNA mixtures with membrane-tethered IL-12 led to the expansion and differentiation of endogenous antigen-specific Th1 helper T cells in vivo. Importantly, this platform activated NY-ESO-1-specific CD8 T cells both in human PBMCs in vitro and in HLA-A*02:01-transgenic mice, highlighting its translational potential. This modular mRNA strategy reprograms somatic cells in situ into designer APCs, providing a flexible and translatable platform for precision immunotherapy.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine 96%
- In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer 96%
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 96%
Similar papers in this journal
- Intratumor Childhood Vaccine-Specific CD4+ T cell Recall Coordinates Antitumor CD8+ T cells and Eosinophils 97%
- Distinct sets of molecular characteristics define tumor-rejecting neoantigens 97%
- A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development of a New Family of Immune Therapies for Cancer 97%
Similar papers in this journal
- Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Immunity 95%
- Visualizing lipid nanoparticle trafficking for mRNA vaccine delivery in non-human primates 94%
- A functional screening platform for engineering chimeric antigen receptors with reduced on-target, off-tumour activation 94%
Similar papers in this journal
- Cellular selectivity of STING stimulation determines priming of tumor-specific T cell responses 96%
- Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4+ T cell response 96%
- Quality of vaccination-induced T cell responses is conveyed by polyclonality and high, but not maximum, antigen receptor avidity 96%
Similar papers in this journal
- Clonal spreading of tumor-infiltrating T cells underlies the robust antitumor immune responses 95%
- Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma 95%
- Combining an alarmin HMGN1 peptide with PD-L1 blockade facilitates stem-like CD8+ T cell expansion and results in robust antitumor effects 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.